Nanowear Heart Failure Management Multi-sensor Algorithm

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-08-21

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The NanoSense study is a multi-center, prospective, non-randomized, observational, feasibility, non-significant risk study. The NanoSense study will enroll up to 500 subjects in up to 10 centers in order to collect data which includes at least 150 heart failure hospitalizations in participating subjects.The duration of the NanoSense study is expected to be 2 years. The study device is the Wearable Congestive Heart Failure Management System (WCHFS, also known as SimpleSENSE)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Nanowear Wearable System SimpleSense Validation Trial for Cardiac Output

NCT05629533

Right Heart Catheterization

RECRUITING

Smart Textile Sensor System for Health Monitoring

NCT05473702

Heart Disease Chronic Pulmonary Disease, Chronic Obstructive Blood Pressure +1 more

RECRUITING

Novel Wearable Device for Heart Failure Management

NCT05642650

Heart Failure

UNKNOWN NA

Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF

NCT05865197

CHF Congestive Heart Failure

RECRUITING

Non-invasive Heart Failure Monitoring Using Novel Acceleration Sensors System

NCT01377350

Heart Failure

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

NanoSense is a data collection study to develop a multi-sensor algorithm to predict worsening Heart Failure (HF). Subjects who meet the eligibility criteria and agree to participate in the study will enter the informed consent process in which the subject will be informed about the research study, the voluntary nature of the research and all attendant risks and benefits. Once the subject has been informed and all question answered, the subject will be asked to sign an informed consent document (approved by the local Institutional Review Board). At enrollment, data about subject demographics, cardiac disease history, and comorbidities will be collected. The subject vital signs, blood labs (as available; if an N-terminal pro b-type natriuretic peptide (NT-proBNP) is not available, one will be ordered to coincide with the next lab samples), HF medications and HF assessment measurements will be made and recorded. Subjects will be given a diary to record daily weights, diuretics changes, and weekly HF status. The subject will be fitted with a Nanowear Wearable Congestive Heart Failure System (WCHFS) and educated on the use of the system with attention to proper fit and changing or charging the battery daily depending on the type of battery used. Subjects who have a pacemaker or Implantable Cardioverter Defibrillator (ICD) will undergo pacemaker/ICD interrogation while wearing the device to assure that there are no electrical signals detected that may interfere with pacemaker or ICD function.

The subjects will be asked to wear the device for approximately 12 hours daily including 2 hours prior to sleep and 2 hours after awakening. The follow-up period will be 90 days. At visit 2, the clinical assessment will be repeated and recorded. The device will be retrieved from the subject. In the event that a subject is unable to travel to the investigator's site, the subject will be asked to mail the device back to the sponsor with use of a prepaid mailing package that will be delivered to the subject. Data may be obtained by phone if the subject is unable or unwilling to return for visit 2.

A final contact will be made to the subject at 30 days following visit 2 to determine whether there were any adverse effects that were not previously recognized that may be related to their participation in the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Heart Failure Patients

Patients with primary diagnosis as heart failure

SimpleSENSE

Intervention Type DEVICE

The Nanosense study is observational only. No interventions will be triggered by the SimpleSense device

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SimpleSENSE

The Nanosense study is observational only. No interventions will be triggered by the SimpleSense device

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject has provided informed consent
* Male or female over the age of 18 years
* The patient is either hospitalized with a primary diagnosis of acute or was discharged with a primary diagnosis of acute heart failure within 2 weeks prior to enrollment
* NYHA functional class II-IV at time of enrollment

Exclusion Criteria

* Subject unwilling or unable to comply with wearing the Nanowear Congestive Heart Failure Management System 12 hours daily for up to 90 days.
* Subjects who are limited by angina.
* Severe aortic stenosis.
* Subjects who are hemodynamically unstable requiring support with intravenous vasoactive medications or mechanical circulatory support
* Symptomatic ventricular arrhythmias within the past 6 months.
* Subjects who are pregnant will be excluded from this study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No